ArticleAmerican journal of preventive cardiology2025
Performance of PREVENT and pooled cohort equations for predicting 10-Year ASCVD risk in the UK Biobank.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The PREVENT Risk Equations and Cardiovascular Prevention in East Asia.Journal of atherosclerosis and thrombosis · 2026Review
- Resting Ultrasound Coronary Flow Velocity and Carotid Plaque Improve Clinical Risk Stratification in Asymptomatic Adults Undergoing Cardiovascular Screening.Diagnostics (Basel, Switzerland) · 2026Article
- Body composition phenotypes are key predictors of cardiovascular-kidney-metabolic multimorbidity and long-term mortality: insights from a population-based cohort study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Review
- The therapeutic approach to cardiovascular-kidney-metabolic syndrome.Nature reviews. Nephrology · 2026Review
- The cardiovascular risk continuum: Continuing to challenge the primary and secondary prevention dichotomy.American journal of preventive cardiology · 2026Article
- Bridging the Gap: Multidisciplinary Decision Making to Address Systemic Barriers in Cardiovascular Care.Current cardiology reports · 2026Review
- REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Cardiovascular risk stratification without recalibration: A comparative study of the PREVENT and WHO risk scores in a multiethnic Brazilian cohort.American journal of preventive cardiology · 2026Article
- Population estimates, trends, characteristics and prognostic outcomes of cardiovascular-kidney-liver-metabolic health: A population-based study.American journal of preventive cardiology · 2026Article
- Statin Eligibility Disparities with Transition from the Pooled Cohort Equations to the AHA PREVENT.medRxiv : the preprint server for health sciences · 2026Article
- Observational
- Predicting Risk of Cardiovascular Disease Events (PREVENT) score accuracy among people with HIV in the multicenter CNICS cohort.AIDS (London, England) · 2025Article
- ALADYNOULLI: A Bayesian approach to disease progression modeling for genomic discovery and clinical prediction.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Pooled Cohort Equations (PCE) were created in 2013 to assess ASCVD risk in primary prevention. In 2023 the American Heart Association published the PREVENT equations to assess the risk of cardiovascular disease in primary prevention. The comparative performance of PCE and PREVENT for predicting 10-year ASCVD risk has not been evaluated in an external large-scale epidemiologic cohort. Methods: The study population includes participants of the UK Biobank who were free of clinical cardiovascular disease. 10-year ASCVD risk was calculated using the PCE and PREVENT equations. Harrel's C-Statistics and delta C-Statistics were calculated for males and females to evaluate risk discrimination. Predicted 10-year risks were divided into deciles as well as risk groups for each equation and stratified by sex to compare predicted risk versus observed risk within each risk group, with calibration slopes calculated by decile. Sensitivity and specificity were also analyzed to assess statin eligibility. Results: The final cohort was 368,125 individuals ages 40-73 (mean age 56.2, 54.7 % female, 94.0 % white). The C-statistics for PCE were 0.729 (0.722-0.736) for females and 0.688 (0.683-0.693) for males; C-Statistics for PREVENT were 0.728 (0.721-0.735) for females and 0.687 (0.682-0.692) for males, with delta C-Statistics being 0.001 ( Conclusions: There is no significant difference in 10-year ASCVD risk discrimination between PCE and PREVENT equations. However, the PREVENT equations demonstrate better calibration in the UK Biobank.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.